A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype

Pharmacogenetics

Volumn 6, Issue 5, 1996, Pages 395-401

  Yokoi, Tsuyoshi ^a   Kosaka, Yasuyuki ^a   Chida, Michihiro ^a   Chiba, Kan ^b   Nakamura, Hidefumi ^b   Ishizaki, Takashi ^b   Kinoshita, Moritoshi ^c   Sato, Kunio ^d   Gonzalez, Frank J ^e   Kamataki, Tetsuya ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^d GUNMA UNIVERSITY   (Japan)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bufuralol 1' hydroxylase; Genetic polymorphism; Population study; Xba I RFLP; Yeast expression system

Indexed keywords

BUFURALOL; CYTOCHROME P450 ISOENZYME; SPARTEINE;

ALLELE; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; EXON; GENE DELETION; GENE INSERTION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HUMAN; JAPAN; PHENOTYPE; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; YEAST;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; BLOTTING, SOUTHERN; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; EXONS; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HUMANS; JAPAN; MIXED FUNCTION OXYGENASES; MUTAGENESIS, INSERTIONAL; MUTATION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE; SEQUENCE ANALYSIS, DNA; SPARTEINE;

EID: 10344266435     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199610000-00003     Document Type: Article

References (29)

1. Daly AK, Armstrong M, Monkman SC, Idle ME, Idle JR. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P450 2D6) phenotypes. Pharmacogenetics 1991; 1, 33-41.
2. Dayer P, Balant L, Kupper A, Courvoisier F, Fabre J. Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents. Eur J Clin Pharmacol 1983: 24, 797-799.
3. Dayer P, Leemann T, Marmay A, Rosenthaler J. Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentrations and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol. Eur J Clin Pharmacol 1985: 28, 149-153.
4. Eichelbaum M, Spannbrucker N, Stincke B, Dengler HJ. Defective N-oxidation of sparteine in man: A new pharmacogenetic defect. Eur J Clin Pharmacol 1979: 16, 183-187.
5. Eichelbaum M, Reetz K-P, Schmidt EK, Zekorn C. The genetic polymorphism of sparteine metabolism. Xenobiotica 1986: 16, 465-481.
6. Evans E, Relling MV. Concordance of P450 2D6 debrisoquine hydroxylase phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers. Pharmacogenetics 1991: 1, 143-148.
7. Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL, A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Gemet 1980: 17, 102-105.
8. Gonzalez FJ, Meyer UA. Molecular genetics of the debrisoquinsparteine polymorphism. Clin Pharmacol Ther 1991: 50, 233-238.
9. Gonzalez FJ, Vilbois F, Hardwick JP, McBride OW, Nebert DW, Gelboin HV, Meyer UA. Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acids sequence and assignment of the CYP2D6 locus to chromosome 22. Genomics 1988: 2, 174-179.
10. Gough AC, Miles JS, Spurr NK, Moss JE, Gedigk A, Eichelbaum M, Wolf CR. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature (London) 1990: 347, 773-776.
11. Heim MH, Meyer UA. Evolution of highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics 1992: 14, 49-58.
12. Heim MH, Meyer UA. Genetic polymorphism of debrisoquine oxidation: Restriction fragment analysis and allele-specific amplification of mutant alleles of CYP2D6. Methods Enzymol 1991: 206, 173-183.
13. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou HH, Zhou BJ, Liao CL, Zhang LM. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989: 46, 198-207.
14. Ishizaki T, Eichelbaum M, Horai Y, Hashimoto K, Chiba K, Dengler HJ. Evidence for polymorphic oxidation of sparteine in Japanese subjects. Br J Clin Pharmacol 1987: 23, 482-485.
15. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. J Biol Chem 1990: 265, 17209-17214.
16. Kamataki T, Sugita O, Naminohira S, Kitagawa H. Effects of various compounds on lipid peroxidation mediated by detergent-solubilized rat liver NADPH-cytochrome c reductase. Jpn J Pharmacol 1978: 28, 837-845.
17. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: Sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 1989: 45, 889-904.
18. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951: 193, 265-275.
19. Messing J, Gronenborn B, Muller-Hill B, Hofschneider PH. Filamentous coli phage M13 as a cloning vehicle: insertion of a Hind III fragment of the lac regulatory region in M13 replicative form in vitro. Proc Natl Acad Sci USA 1977: 74, 3642-3646.
20. Nakamura K, Goto F, Ray A, McAllister CB, Jacqz E, Wilkinson GR, Branch RA. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985: 38, 402-408.
21. Oeda K, Sakaki T, Ohkawa H, Expression of rat liver cytochrome P-450MC cDNA in Saccharomyces cerevisiae. DNA 1985: 4, 203-210.
22. Sakuma T, Masaki K, Itoh S, Yokoi T, Kamataki T. Sex related deferences in the expression of cytochrome P450 in hamsters: cDNA cloning and examination of the expression of three distinct CYP2C cDNAs. Mol Pharmacol 1994: 45, 228-236.
23. Sambrook J, Fritsch EE, Maniatis T. Molecular cloning: A laboratory manual, Edn 2. New York: Cold Spring Harbor Laboratory Press. 1989: 9-16-9-19.
24. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chainterminating inhibitors. Proc Natl Acad Sci USA 1977: 74, 5463-5467.
25. Saxena R, Shaw GL, Relling MV, Frame JN, Moir DT, Evans WE, Caporaso N, Weiffenbach B. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum Mol Genet 1994: 3, 923-926.
26. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA. Two mutant alleles of the human cytochrome P450db1 gene (P-450IID1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 1988: 85, 5240-5243.
27. Sohn DR, Shin SG, Park CW, Kusaka M, Chiba K, Ishizaki T. Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. Br J Clin Pharmacol 1991: 32, 504-507.
28. Tyndale R, Aoyama T, Broly F, Matsunaga T, Inaba T, Kalow W, Gelboin HV, Meyer UA, Gonzalez FJ. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics 1991: 1, 26-32.
29. Yokota H, Tamura S, Furuya H, Kimura S, Watanabe M, Kanazawa I, Kondo I, Gonzalez FJ. Evidence for a new variant CYP2D6 allele CYP2D6J in rates of sparteine metabolism. Pharmacogenetics 1993: 3, 256-263.